ASH 2021 | Glofitamab and polatuzumab vedotin in DLBCL
Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents findings from the open-label, Phase Ib/II trial (NCT03533283) trial of glofitamab, a CD20xCD3 T-cell-engaging bispecific antibody, with polatuzumab vedotin, an antibody-drug conjugate, in patients with diffuse large B-cell lymphoma (DLBCL). An encouraging safety profile was observed, with no cases of grade 3 or higher cytokine release syndrome (CRS) observed, which can be attributed to prior administration of obinutuzumab and polatuzumab vedotin. The treatment combination additionally demonstrated promising efficacy, with half of patients reporting a complete response. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
